Abstract: Aspects of the invention are directed to methods of treating cancer using a combination of spherical nucleic acids (SNAs) and a checkpoint inhibitor. The SNA molecule comprises a core oligonucleotide shell of CpG oligonucleotides positioned on the exterior of this core. The SNA is administered at a fixed dose of 2mg to a solid tumour or tumour lesion, and is administered within 24 hours of the checkpoint inhibitor administration. The SNA can also be administered at a dose of 700 mg-900 mg every 2 weeks. The SNA can also be a CpG linked via a spacer to the exterior surface of a liposome core of 40 nm or less diameter.

Abstract: Optimized inhibitory nucleic acids are provided. The nucleic acids have sequences which include an optimal inhibitory motif, such as GGG. Related methods are also described.

Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or disorders using the TNF? antisense oligonucleotides and related products are provided.

Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or Initial Screen of Phosphodiester disorders using the TNF? antisense oligonucleotides and related products are provided.

Abstract: Optimized inhibitory nucleic acids are provided. The nucleic acids have sequences which include an optimal inhibitory motif, such as a GGG. Related methods are also described.

Abstract: A method of improving the measurement accuracy of a digital ice rate sensor by providing an enhanced surface finish on a magnetostrictive oscillator detector probe by measuring the surface roughness of the detector probe, comparing the measured value to a critical value, and authorizing the probe for use in the digital ice rate sensor if surface roughness is within the critical value. Surface roughness may be measured optically or with a surface profilometer. Remedial steps taken if surface roughness is not within the critical value include reworking the probe surface finish and investigating the manufacturing process.

Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or disorders using the TNF? antisense oligonucleotides and related products are provided.

Abstract: A method of improving the measurement accuracy of a digital ice rate sensor by providing an enhanced surface finish on a magnetostrictive oscillator detector probe by measuring the surface roughness of the detector probe, comparing the measured value to a critical value, and authorizing the probe for use in the digital ice rate sensor if surface roughness is within the critical value. Surface roughness may be measured optically or with a surface profilometer. Remedial steps taken if surface roughness is not within the critical value include reworking the probe surface finish and investigating the manufacturing process.

Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or disorders using the TNF? antisense oligonucleotides and related products are provided.

Abstract: A system includes a device having a first surface configured to be exposed to airflow about an exterior of an aircraft, the device including a first self-compensating heater configured to heat the first surface, a first current monitor configured to sense a first measurement value representing electrical current flow through the first self-compensating heater, one or more processors, and computer-readable memory encoded with instructions that, when executed by the one or more processors, cause the system to receive aircraft flight condition data and produce an icing condition signal based upon the first measurement value and the aircraft flight condition data.

Abstract: Optimized inhibitory nucleic acids are provided. The nucleic acids have sequences which include an optimal inhibitory motif, such as a GGG. Related methods are also described.

Abstract: A system includes a device having a first surface configured to be exposed to airflow about an exterior of an aircraft, the device including a first self-compensating heater configured to heat the first surface, a first current monitor configured to sense a first measurement value representing electrical current flow through the first self-compensating heater, one or more processors, and computer-readable memory encoded with instructions that, when executed by the one or more processors, cause the system to receive aircraft flight condition data and produce an icing condition signal based upon the first measurement value and the aircraft flight condition data.

Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or Initial Screen of Phosphodiester disorders using the TNF? antisense oligonucleotides and related products are provided.

Abstract: Articles, compositions, kits, and methods relating to nanostructures, including those that can sequester molecules such as cholesterol, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanoparticle core may be surrounded by a shell including a material, such as a lipid bilayer, that can interact with cholesterol and/or other lipids. In some embodiments, the structures, when introduced into a subject, can sequester cholesterol and/or other lipids and remove them from circulation. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions, especially those associated with abnormal lipid levels.

Abstract: Exemplary embodiments are directed to detection and validation of wirelessly chargeable devices positioned within a charging region of a wireless power transmitter. A device may include a detection circuit comprising an oscillator, the detection circuit configured to detect a change in a frequency of the oscillator. The device may also include a wireless power transmitter configured to determine whether a chargeable device is positioned within a charging region of the transmitter upon the detection circuit detecting the change in the frequency of the oscillator, wherein the transmitter further configured to be selectively electrically isolated from the detection circuit.

Abstract: Exemplary embodiments are directed to detection and validation of wirelessly chargeable devices positioned within a charging region of a wireless power transmitter. A device may include a detection circuit comprising an oscillator, the detection circuit configured to detect a change in a frequency of the oscillator. The device may also include a wireless power transmitter configured to determine whether a chargeable device is positioned within a charging region of the transmitter upon the detection circuit detecting the change in the frequency of the oscillator, wherein the transmitter further configured to be selectively electrically isolated from the detection circuit.

Abstract: Articles, compositions, kits and methods relating to nanostructures, including those that can sequester molecules such as cholesterol, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanoparticle core may be surrounded by a shell including a material, such as a lipid bilayer, that can interact with cholesterol and/or other lipids, and an apolipoprotein may be bound to at least the outer surface of the shell. In some embodiments, the structures, when introduced to a subject, can sequester cholesterol and/or other lipids and remove them from circulation. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions, especially those associated with abnormal lipid levels.

Abstract: Articles, compositions, kits, and methods relating to nanostructures, including those that can sequester molecules such as cholesterol, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanoparticle core may be surrounded by a shell including a material, such as a lipid bilayer, that can interact with cholesterol and/or other lipids. In some embodiments, the structures, when introduced into a subject, can sequester cholesterol and/or other lipids and remove them from circulation. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions, especially those associated with abnormal lipid levels.

Abstract: Articles, compositions, kits, and methods relating to nanostructures, including those that can sequester molecules such as cholesterol, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanoparticle core may be surrounded by a shell including a material, such as a lipid bilayer, that can interact with cholesterol and/or other lipids. In some embodiments, the structures, when introduced into a subject, can sequester cholesterol and/or other lipids and remove them from circulation. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions, especially those associated with abnormal lipid levels.